Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASOX neoadjuvant therapy for resectable or borderline resectable pancreatic cancer
ChiCTR2300079198Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Dec 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoliposomal irinotecan, oxaliplatin and tegafur in pancreatic cancer (PC), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoint: Objective response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatintegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300079198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079198.